Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy

Table 4 Univariate and multivariate analysis of clinical factors associated with progression events

Characteristic	Univariate			Multivariate
Characteristic	HR	95%CI	P value	HR	95%CI	P value
Age	1.00	(0.97–1.0)	0.6
Sex	4.2e−10	(0-Inf)	1
Tumor size	1.00	(0.93–1.1)	0.59
Tumor number	3.70	(1.1–12.0)	0.035*	4.64	1.03–20.88	0.045
HBV	0.33	(0.1–0.99)	0.048*
AFP	0.94	(0.42–2.1)	0.88
GGT	1.10	(0.42–2.7)	0.89
ALP	0.83	(0.38–1.8)	0.65
AST	0.58	(0.24–1.4)	0.23
Child–Pugh	1.00	(0.23–4.3)	0.99
BCLC	1.40	(0.63–3.0)	0.42
PLR	1.50	(0.66–3.4)	0.33
LMR	1.80	(0.76–4.2)	0.18
PNI	1.30	(0.55–3.0)	0.57
SII	1.70	(0.75–3.8)	0.21
NLR	0.62	(0.21–1.8)	0.39
Location	1.70	(0.80–3.8)	0.16
Tumor margin	1.00	(0.44–2.4)	0.93
Types of gross growth	1.80	(1.1–3.0)	0.038*	1.15	0.6–2.17	0.676
ADC intensity display	1.00	(0.11–2.4)	0.93
Signal homogeneity on T2WI	0.82	(0.36–1.8)	0.63
Intensity enhancement on arterial phase	0.35	(0.15–0.8)	0.013*	0.24	0.09–0.64	0.004
Expansion of arterial phase range	0.35	(0.15–0.8)	0.81
Type of enhancement	0.56	(0.24–1.3)	0.17
Arterial peritumoral enhancement	0.86	(0.35–2.1)	0.73
Enhancing tumor capsule	0.77	(0.35–1.7)	0.53
Hepatic capsule bulge	0.54	(0.24–1.2)	0.14
Scarring centrally	0.34	(0.08–1.5)	0.15
Hemorrhage	0.53	(0.07–4.2)	0.55
Necrosis	2.20	(0.91–5.5)	0.079
Fat	0.22	(0.03–1.8)	0.15
Massive vein tumor thrombosis	0.85	(0.44–1.6)	0.62
Metastasis in distant areas	1.76	(0.83–3.7)	0.14

HBV was not selected. Because only 4 patients did not have hepatitis B. Based on clinical considerations, it was not subjected to multivariate analysis
*P < 0.05

ISSN: 1471-230X